Global Organ Transplant Immunosuppressant Drugs Market Size To Exceed USD 8.55 Billion By 2035 | CAGR of 4.53% during
Category: HealthcareGlobal Organ Transplant Immunosuppressant Drugs Market Size To Exceed USD 8.55 Billion By 2035
According to a research report published by Spherical Insights & Consulting, the Global Organ Transplant Immunosuppressant Drugs Market Size is Expected to Grow from USD 5.25 Billion in 2024 to USD 8.55 Billion by 2035, at a CAGR of 4.53% during the forecast period 2025-2035.
Get more details on this report -
Browse key industry insights spread across 230 pages with 130 Market data tables and figures & charts from the report on the "Global Organ Transplant Immunosuppressant Drugs Market Size, Share, and COVID-19 Impact Analysis, By Drug Class (Calcineurin Inhibitors, Antiproliferative Agents, mTOR Inhibitor, Steroids, and Other Drug Classes), By Transplant Type (Kidney, Liver, Heart, Lung, Pancreas, and Other Transplant Types), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 – 2035." Get Detailed Report Description Here:https://www.sphericalinsights.com/reports/organ-transplant-immunosuppressant-drugs-market
The organ transplant immunosuppressant drugs market is the market encompassing the medications that suppress the immune system in transplant recipients, preventing rejection of the transplanted organ. The increasing prevalence of autoimmune diseases such as arthritis, multiple sclerosis, and alopecia, as well as the prevalence of organ failure, is driving the demand for organ transplant treatments, resulting in a market demand. An integration of AI and ML for optimization of immunosuppression protocols in organ transplants, as well as the development of personalized therapy, is escalating the market growth opportunities. An increasing number of organ transplants, which is estimated to be 172,397 organ transplants in 2023, is anticipated to propel the market. Further, the increasing prevalence of chronic diseases, the aging population, and advancements in medical care are contributing to driving the market growth. On the contrary, the high cost and side effects associated with these immunosuppressant drugs are restraining the market.
The calcineurin inhibitors segment dominated the market with the largest share of 41.5% in 2024 and is projected to grow at the fastest CAGR during the forecast period.
Based on the drug class, the organ transplant immunosuppressant drugs market is divided into calcineurin inhibitors, antiproliferative agents, mTOR inhibitor, steroids, and other drug classes. Among these, the calcineurin inhibitors segment dominated the market with the largest share of 41.5% in 2024 and is projected to grow at the fastest CAGR during the forecast period. The use of calcineurin inhibitors like cyclosporine and tacrolimus for preventing body rejection of transplanted tissues and reducing inflammation is driving the market in the calcineurin inhibitors segment.
The kidney segment held the largest market share of 49.1% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period.
Based on the transplant type, the organ transplant immunosuppressant drugs market is divided into kidney, liver, heart, lung, pancreas, and other transplant types. Among these, the kidney segment held the largest market share of 49.1% in 2024 and is anticipated to grow at a remarkable CAGR during the forecast period. In kidney transplantation, triple therapy is the most common immunosuppression regime used for preventing rejection of the transplanted kidney. An increasing prevalence of kidney diseases and kidney transplants, along with increasing advancements in immunosuppressive therapies anticipated to propel the market growth.
North America is expected to hold the majority share of the global organ transplant immunosuppressant drugs market during the forecast period.
Get more details on this report -
North America is expected to hold the majority share of the global organ transplant immunosuppressant drugs market during the forecast period. An increasing prevalence of chronic diseases is likely to drive the market demand for organ transplant immunosuppressant drugs. Further, an increasing number of organ transplants and the need for immunosuppression for preventing graft rejection are contributing to propel the market demand.
Asia Pacific is anticipated to grow at the fastest pace in the global organ transplant immunosuppressant drugs market during the forecast period. Several factors, including the prevalence of chronic diseases, the increasing number of organ transplants, and initiatives for creating awareness about organ donation, are contributing to driving the market for organ transplant immunosuppressant drugs.
Europe is anticipated to hold a significant share of the organ transplant immunosuppressant drugs market during the predicted timeframe. The presence of well-established healthcare infrastructure, supportive government policies, and the presence of leading market players significantly contributes to regional market growth.
Major vendors in the global organ transplant immunosuppressant drugs market are Astellas Pharma d.o.o., Sanofi, Accord Healthcare, Novartis AG, Viatris Inc., F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc., Veloxis Pharmaceuticals, Inc., Bristol-Myers Squibb Company, and Others.
Key Target Audience
- Market Players
- Investors
- End-users
- Government Authorities
- Consulting and Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
Key Market Development
- In April 2024, United Therapeutics Corporation, a public benefit corporation, announced the world’s first successful transplant of a UThymoKidney, which the company produced, into a living person.
- In February 2022, Veloxis Pharmaceuticals, Inc., an Asahi Kasei company, announced that VEL-101, a novel investigational maintenance immunosuppressive agent being developed for prophylaxis of renal allograft rejection in patients receiving a kidney transplant, was granted fast-track designation by the US FDA.
Market Segment
This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the organ transplant immunosuppressant drugs market based on the below-mentioned segments:
Global Organ Transplant Immunosuppressant Drugs Market, By Drug Class
- Calcineurin Inhibitors
- Antiproliferative Agents
- mTOR Inhibitor
- Steroids
- Other Drug Classes
Global Organ Transplant Immunosuppressant Drugs Market, By Transplant Type
- Kidney
- Liver
- Heart
- Lung
- Pancreas
- Other Transplant Types
Global Organ Transplant Immunosuppressant Drugs Market, By Regional Analysis
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Rest of Asia Pacific
- South America
- Brazil
- Argentina
- Rest of South America
- Middle East & Africa
- UAE
- Saudi Arabia
- Qatar
- South Africa
- Rest of the Middle East & Africa
About the Spherical Insights & Consulting
Spherical Insights & Consulting is a market research and consulting firm which provides actionable market research study, quantitative forecasting and trends analysis provides forward-looking insight especially designed for decision makers and aids ROI.
Which is catering to different industry such as financial sectors, industrial sectors, government organizations, universities, non-profits and corporations. The company's mission is to work with businesses to achieve business objectives and maintain strategic improvements.
CONTACT US:
For More Information on Your Target Market, Please Contact Us Below:
Phone: +1 303 800 4326 (the U.S.)
Phone: +91 90289 24100 (APAC)
Email: inquiry@sphericalinsights.com, sales@sphericalinsights.com
Contact Us: https://www.sphericalinsights.com/contact-us
Need help to buy this report?